Guangzhou Linglu Technology Beauty Co., Ltd. – Trademark Portfolio

Entity Type: 99

Guangzhou Linglu Technology Beauty Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FUMOOEAN. The owner is based in Guangzhou City.

Room 401, Building 1, No. 4 Xia Liang Road, Baiyun District,

Guangzhou City 510000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FUMOOEAN
FUMOOEAN
Registered 2026

Trademark Classifications

Guangzhou Linglu Technology Beauty Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Guangzhou Linglu Technology Beauty Co., Ltd. have?

Guangzhou Linglu Technology Beauty Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Guangzhou Linglu Technology Beauty Co., Ltd. file in?

Guangzhou Linglu Technology Beauty Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Guangzhou Linglu Technology Beauty Co., Ltd.'s most well-known trademarks?

Guangzhou Linglu Technology Beauty Co., Ltd.'s registered trademark portfolio includes well-known marks such as FUMOOEAN. These are among 1 currently registered trademark in the portfolio.

What is Guangzhou Linglu Technology Beauty Co., Ltd.'s trademark registration success rate?

Guangzhou Linglu Technology Beauty Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.